Proton-Pump Inhibitor Use and Risk for Community-Acquired Pneumonia

In patients with community-acquired pneumonia, PPI use was associated with a twofold increased risk for infection with oropharyngeal bacteria but not other pathogenic agents.

The decrease in gastric acidity that results from treatment with proton-pump inhibitors (PPIs) has been linked with bacterial colonization of the stomach and outcomes such as nosocomial pneumonia in the inpatient setting (Ann Intern Med 1994; 120:653) and community-acquired pneumonia (CAP; JAMA 2004; 292:1955).

To further investigate the possible link between PPI use and CAP, investigators prospectively assessed PPI use and microbiological etiology of pneumonia in patients treated for CAP in the emergency room of a large general hospital in the Netherlands. A diagnosis of CAP was based on symptoms and radiographic findings. Microbiological etiology of the pneumonia infection was assessed using sputum and blood cultures, urine antigen tests, …

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Proton-Pump Inhibitor Use and Risk for Community-Acquired Pneumonia

Topics

Reviewing Author